ID23503A - Garam-garam sertralina dan bentuk-bentuk sediaan lepas-lambat dari sertralina - Google Patents

Garam-garam sertralina dan bentuk-bentuk sediaan lepas-lambat dari sertralina

Info

Publication number
ID23503A
ID23503A IDW991704A ID991704A ID23503A ID 23503 A ID23503 A ID 23503A ID W991704 A IDW991704 A ID W991704A ID 991704 A ID991704 A ID 991704A ID 23503 A ID23503 A ID 23503A
Authority
ID
Indonesia
Prior art keywords
sertralina
sales
detailed forms
mga
sertraline
Prior art date
Application number
IDW991704A
Other languages
English (en)
Indonesian (id)
Inventor
Mary Tanya Am Ende
William John Curatolo
Hylar Lewis Friedman
Ravi Mysore Shanker
Scott Max Herbig
Dwayne Thomas Friesen
James Blair West
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of ID23503A publication Critical patent/ID23503A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IDW991704A 1997-07-01 1998-06-15 Garam-garam sertralina dan bentuk-bentuk sediaan lepas-lambat dari sertralina ID23503A (id)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5142097P 1997-07-01 1997-07-01
US5141497P 1997-07-01 1997-07-01
US5149897P 1997-07-01 1997-07-01
US5140297P 1997-07-01 1997-07-01

Publications (1)

Publication Number Publication Date
ID23503A true ID23503A (id) 2000-04-27

Family

ID=27489408

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW991704A ID23503A (id) 1997-07-01 1998-06-15 Garam-garam sertralina dan bentuk-bentuk sediaan lepas-lambat dari sertralina

Country Status (33)

Country Link
US (1) US6517866B1 (ko)
EP (1) EP0999830A1 (ko)
JP (1) JP2000514101A (ko)
KR (2) KR100412327B1 (ko)
CN (1) CN1256085C (ko)
AP (1) AP1526A (ko)
AR (2) AR015919A1 (ko)
AU (1) AU739261B2 (ko)
BG (1) BG103915A (ko)
BR (1) BR9810403A (ko)
CA (1) CA2290966C (ko)
CO (1) CO4940402A1 (ko)
DZ (1) DZ2546A1 (ko)
EA (1) EA002482B1 (ko)
HK (1) HK1026630A1 (ko)
HR (1) HRP980379B1 (ko)
HU (1) HUP0002296A3 (ko)
ID (1) ID23503A (ko)
IL (2) IL133080A0 (ko)
IS (1) IS5265A (ko)
MY (1) MY129175A (ko)
NO (1) NO996518L (ko)
NZ (2) NZ501251A (ko)
OA (1) OA11245A (ko)
PA (1) PA8454401A1 (ko)
PE (1) PE88699A1 (ko)
PL (1) PL337806A1 (ko)
SK (1) SK180499A3 (ko)
TN (1) TNSN98125A1 (ko)
TR (1) TR199903280T2 (ko)
TW (1) TWI241188B (ko)
UY (1) UY25067A1 (ko)
WO (1) WO1999001121A1 (ko)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208926A1 (en) * 1997-07-01 2004-10-21 Pfizer Inc Solubilized sertraline compositions
DK1067910T3 (da) * 1998-04-03 2004-10-04 Egalet As Komposition med styret afgivelse
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
DE60035579T2 (de) * 1999-05-20 2008-04-17 Elan Corp. Plc Multipartikuläre arzneizusammensetzungen mit gesteuerter wirkstoffabgabe enthaltend selektive inhibitoren der serotoninwiederaufnahme
IE990406A1 (en) 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
EP1671628B1 (en) * 1999-09-03 2012-10-03 APBI Holdings, LLC Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
GB9923045D0 (en) * 1999-09-29 1999-12-01 Novartis Ag New oral formulations
CA2395231C (en) * 1999-12-23 2006-08-15 Pfizer Products Inc. Hydrogel-driven layered drug dosage form
US6620431B1 (en) * 2000-04-17 2003-09-16 Charles Signorino Shellac film coatings providing release at selected pH and method
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
EP1313473A2 (en) 2000-08-30 2003-05-28 Pfizer Products Inc. Sustained release formulations for growth hormone secretagogues
US6482440B2 (en) * 2000-09-21 2002-11-19 Phase 2 Discovery, Inc. Long acting antidepressant microparticles
SE0004671D0 (sv) 2000-12-15 2000-12-15 Amarin Dev Ab Pharmaceutical formulation
JP2002212062A (ja) * 2001-01-24 2002-07-31 Teijin Ltd 遅延放出制御組成物
WO2002064114A1 (en) * 2001-02-15 2002-08-22 Sanwa Kagaku Kenkyusho Co., Ltd. Novel ophthalmic compositions
US6946146B2 (en) * 2001-04-18 2005-09-20 Nostrum Pharmaceuticals Inc. Coating for a sustained release pharmaceutical composition
HUP0401941A3 (en) * 2001-07-16 2008-04-28 Astrazeneca Ab Pharmaceutical formulation comprising a proton pomp inhibitor and antacids and process for its preparation
US20040253310A1 (en) * 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
EP2957281A1 (en) * 2001-09-21 2015-12-23 Egalet Ltd. Polymer release system
ATE376826T1 (de) * 2001-09-28 2007-11-15 Mcneil Ppc Inc Darreichungsformen zur modifizierten freisetzung
US7005138B2 (en) * 2001-12-21 2006-02-28 Duramed Pharmaceuticals, Inc. Method of systematically delivering SSRIs
US7670612B2 (en) 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
US20100189797A1 (en) 2002-06-10 2010-07-29 Julien Mendlewicz Oral antidepressant formulation
US20050226926A1 (en) * 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
WO2004024130A2 (en) * 2002-09-16 2004-03-25 Sepracor, Inc. TREATMENT OF CNS DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-N-METHYL-1-NAPTHALENAMINE
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
CA2415154C (en) * 2002-12-24 2009-06-16 Biovail Laboratories Inc. Modified release formulations of selective serotonin re-uptake inhibitors
WO2004065348A1 (en) * 2003-01-23 2004-08-05 Pfizer Products Inc. Pharmaceutically acceptable salts of sertraline and pharmaceutical compositions thereof
US20040224876A1 (en) * 2003-02-14 2004-11-11 Jost-Price Edward Roydon Combination therapy for the treatment of immunoinflammatory disorders
WO2004084868A1 (en) * 2003-03-26 2004-10-07 Egalet A/S Morphine controlled release system
EP1613333A1 (en) * 2003-04-04 2006-01-11 Pharmacia Corporation Oral extended release compressed tablets of multiparticulates
RU2391093C2 (ru) 2003-04-24 2010-06-10 Джаготек Аг Таблетка замедленного высвобождения с заданной геометрией ядра
JP2007502329A (ja) * 2003-05-23 2007-02-08 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド セルトラリン組成物
RS51934B (en) * 2003-08-08 2012-02-29 Biovail Laboratories International Srl. BUPROPION HYDROCHLORIDE TABLE WITH MODIFIED RELEASE
RU2376279C2 (ru) * 2003-11-04 2009-12-20 Сипла Лимитед Способ получения полиморфов ингибитора повторного захвата серотонина (варианты)
PE20060003A1 (es) * 2004-03-12 2006-03-01 Smithkline Beecham Plc Formulacion farmaceutica polimerica para moldear por inyeccion
KR100772980B1 (ko) * 2004-04-01 2007-11-02 한미약품 주식회사 메트포르민의 경구투여용 서방성 제제
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
ITMI20041295A1 (it) * 2004-06-25 2004-09-25 Cosmo Spa Composizioni farmaceutiche antimicrobiche orali
EP2135602A1 (en) 2004-08-13 2009-12-23 Boehringer Ingelheim International GmbH Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
KR100920856B1 (ko) * 2004-11-30 2009-10-09 (주)아모레퍼시픽 선택적 세로토닌 재흡수 억제제의 연장방출 제제 및 그제조방법
WO2006072878A1 (en) * 2005-01-07 2006-07-13 Ranbaxy Laboratories Limited Oral dosage forms of sertraline having controlled particle size and processes for their preparation
US20080274183A1 (en) * 2005-02-04 2008-11-06 Phillip Michael Cook Thermoplastic articles containing a medicament
CA2601800C (en) * 2005-03-14 2013-12-03 Nitin Bhalachandra Dharmadhikari Oral drug delivery system
CA2611081C (en) * 2005-06-03 2016-05-31 Egalet A/S A drug delivery system for delivering active substances dispersed in a dispersion medium
US8747897B2 (en) * 2006-04-27 2014-06-10 Supernus Pharmaceuticals, Inc. Osmotic drug delivery system
US7893053B2 (en) * 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
MY149863A (en) 2006-08-03 2013-10-31 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid disease
AU2008207200B2 (en) * 2007-01-16 2011-02-17 Egalet Ltd Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
CA2687192C (en) 2007-06-04 2015-11-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
WO2009034431A2 (en) 2007-09-10 2009-03-19 Pfizer Inc. Controlled-release dosage forms for varenicline
AU2009281537A1 (en) * 2008-08-14 2011-06-30 Bioneer A/S Coated tablets with a remaining degradation surface over the time
DE102008051572A1 (de) 2008-09-05 2010-03-11 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Herstellung von Phosphatbindern und auf diese Weise hergestellte Phosphatbinder
AU2008243202B2 (en) * 2008-11-11 2015-08-20 Cosmo Technologies Ltd Oral antimicrobial pharmaceutical compositions
CA2751667C (en) 2009-02-06 2016-12-13 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
NZ597283A (en) 2009-06-24 2013-07-26 Egalet Ltd Controlled release formulations
EP2498764B1 (en) 2009-11-09 2017-09-06 Spotlight Technology Partners LLC Fragmented hydrogels
JP5864429B2 (ja) 2009-11-09 2016-02-17 スポットライト テクノロジー パートナーズ エルエルシーＳｐｏｔｌｉｇｈｔ Ｔｅｃｈｎｏｌｏｇｙ Ｐａｒｔｎｅｒｓ Ｌｌｃ 架橋ヒドロゲル組成物、ヒドロゲル組成物の形成方法、及びキット
EA201590165A1 (ru) 2012-07-06 2015-08-31 Эгалет Лтд. Сдерживающие злоупотребление фармацевтические композиции для контролируемого высвобождения
JP6041823B2 (ja) * 2013-03-16 2016-12-14 ファイザー・インク トファシチニブの経口持続放出剤形
WO2016020936A2 (en) * 2014-07-21 2016-02-11 Patel Jayendrakumar Dasharathlal A novel oral gastroretentive pharmaceutical dosage form
CN104402705B (zh) * 2014-11-04 2017-04-12 成都理工大学 球形柠檬酸钙及其制备方法和应用
JP6455293B2 (ja) * 2015-04-21 2019-01-23 ニプロ株式会社 セルトラリン及び／又はその薬学上許容しうる塩を含む製剤
MX2020003854A (es) * 2017-10-05 2020-11-13 Purac Biochem Bv Polvo de lactato y metodo para la preparacion del mismo.
CN109432038A (zh) * 2018-12-28 2019-03-08 乐普制药科技有限公司 一种含有盐酸舍曲林的肠溶片剂及其制备方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
DK150008C (da) 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US5112619A (en) 1985-11-12 1992-05-12 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulation
US4847092A (en) 1985-11-12 1989-07-11 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulations
US4797286A (en) 1985-11-12 1989-01-10 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulations
US4803076A (en) * 1986-09-04 1989-02-07 Pfizer Inc. Controlled release device for an active substance
DE3700420A1 (de) 1986-12-22 1988-07-07 Efka Werke Kiehn Gmbh Fritz Tabakerzeugnis fuer die selbstverfertigung einer zigarette, insbesondere filter-zigarette
US5135947A (en) 1987-04-09 1992-08-04 Eli Lilly And Company 1-phenyl-3-naphthalenyloxypropanamines and their use as selective serotonin reuptake inhibitors
US4839104A (en) 1987-06-11 1989-06-13 Pfizer, Inc. Process for preparing sertraline intermediates
US4777288A (en) 1987-06-11 1988-10-11 Pfizer Inc. Process for preparing a 4,4-diphenylbutanoic acid derivative
US4792448A (en) 1987-06-11 1988-12-20 Pfizer Inc. Generic zero order controlled drug delivery system
US4971998A (en) 1987-10-22 1990-11-20 Massachusetts Institute Of Technology Methods for treating the premenstrual or late luteal phase syndrome
US4876282A (en) 1987-11-25 1989-10-24 Eli Lilly And Company 1-Phenylalkylamines as selective serotonin uptake inhibitors
US4855500A (en) 1988-05-04 1989-08-08 Pfizer Inc. Process for preparing a ketimine
US5026707A (en) 1988-05-23 1991-06-25 Eli Lilly And Company Ring-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes
IL91398A (en) * 1988-08-30 1994-05-30 Pfizer A device for the controlled release of pneumatic substances, including the active substance, surrounded by an asymmetric membrane
IL114715A (en) 1989-02-27 1997-01-10 Lilly Co Eli Intermediate compounds for ring-substituted 2-amino-1, 2, 3, 4-tetrahydronaphthalenes and 3-aminochromanes
US4981870A (en) 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
US4983401A (en) 1989-05-22 1991-01-08 Kinaform Technology, Inc. Sustained release pharmaceutical preparations having pH controlled membrane coatings
US5130338A (en) 1989-08-30 1992-07-14 Pfizer Inc. Method of treating chemical dependencies using sertraline
US4940731A (en) 1989-08-30 1990-07-10 Pfizer Inc. Method of treating premature ejaculation using sertraline
DE69004529T2 (de) 1989-08-30 1994-02-24 Pfizer Verwendung von Sertralin zur Behandlung von Abhängigkeiten von chemischen Stoffen.
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
WO1992000103A1 (en) 1990-06-28 1992-01-09 Beecham Group Plc Pharmaceutical preparations
ES2067957T3 (es) 1990-08-07 1995-04-01 Pfizer Uso de membranas polimerizadas interfacialmente en dispositivos de liberacion.
AU8629691A (en) 1990-08-09 1992-03-02 Massachusetts Institute Of Technology Method for treating the premenstrual or late luteal phase syndrome
US5104899A (en) 1990-08-13 1992-04-14 Sepracor, Inc. Methods and compositions for treating depression using optically pure fluoxetine
WO1992009281A2 (en) 1990-11-24 1992-06-11 Beecham Group Plc Use of paroxetine for the treatment of senile dementia, bulimia, migraine or anorexia
NZ241495A (en) 1991-02-08 1994-10-26 Lilly Co Eli 2-amino-1,2,3,4-tetrahydronaphthalene and 3-aminochromane derivative, preparation and pharmaceutical compositions thereof
AU1919592A (en) 1991-04-16 1992-11-17 National Institutes Of Health Method of treating trichotillomania and onychophagia
US5196607A (en) 1992-02-14 1993-03-23 Pfizer Inc. Process for preparing ketone enantiomer
ATE173159T1 (de) 1992-03-25 1998-11-15 Depomed Systems Inc Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe
US5518730A (en) 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
US5248699A (en) 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
US6440457B1 (en) 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
IE930485A1 (en) 1993-06-28 1994-12-28 Hemisphere Ltd Antidepressant agents with a rapid onset of action
US5597826A (en) 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
DE69525847T2 (de) 1994-09-19 2002-09-05 Du Pont Pharm Co Zusammensetzungen von opioid antagonisten mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von alkoholismus und alkohoabhängigkeit
ES2192217T3 (es) 1995-07-17 2003-10-01 Pfizer Sertralina para el tratamiento de pacientes tras un infarto de miocardio.
GB9514842D0 (en) 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
BR9708254A (pt) 1996-03-25 1999-08-03 Lilly Co Eli Método para o tratamento da dor
ZA97976B (en) 1996-04-05 1997-08-18 Alza Corp Uniform drug delivery theraphy.
US5741807A (en) 1996-09-27 1998-04-21 Cytos Pharmaceuticals, L.P. Histidine compositions and methods for treating or preventing infectious and non-infectious diarrheas
US6590083B1 (en) 1999-04-16 2003-07-08 Ortho-Mcneil Pharmaceutical, Inc. Ketolide antibacterials

Also Published As

Publication number Publication date
IS5265A (is) 1999-11-23
TWI241188B (en) 2005-10-11
EA002482B1 (ru) 2002-06-27
NO996518L (no) 2000-02-29
KR20040004367A (ko) 2004-01-13
NZ501251A (en) 2001-09-28
CO4940402A1 (es) 2000-07-24
OA11245A (en) 2003-07-23
BG103915A (en) 2000-07-31
HRP980379A2 (en) 1999-04-30
PL337806A1 (en) 2000-09-11
US6517866B1 (en) 2003-02-11
CN1256085C (zh) 2006-05-17
TNSN98125A1 (fr) 2005-03-15
HRP980379B1 (en) 2003-04-30
AR065827A2 (es) 2009-07-08
IL133080A0 (en) 2001-03-19
KR20010014043A (ko) 2001-02-26
IL152330A0 (en) 2003-05-29
CA2290966C (en) 2005-12-20
WO1999001121A1 (en) 1999-01-14
JP2000514101A (ja) 2000-10-24
KR100412327B1 (ko) 2003-12-31
SK180499A3 (en) 2001-08-06
EA199900964A1 (ru) 2000-08-28
BR9810403A (pt) 2000-08-29
NZ513456A (en) 2003-02-28
TR199903280T2 (xx) 2000-11-21
EP0999830A1 (en) 2000-05-17
UY25067A1 (es) 2000-12-29
AU739261B2 (en) 2001-10-11
CA2290966A1 (en) 1999-01-14
HUP0002296A3 (en) 2001-11-28
PE88699A1 (es) 1999-09-20
NO996518D0 (no) 1999-12-28
AU7544998A (en) 1999-01-25
PA8454401A1 (es) 2000-05-24
HUP0002296A2 (hu) 2001-10-28
MY129175A (en) 2007-03-30
AR015919A1 (es) 2001-05-30
HK1026630A1 (en) 2000-12-22
AP9801281A0 (en) 1998-06-30
DZ2546A1 (fr) 2003-02-08
AP1526A (en) 2006-01-03
CN1261793A (zh) 2000-08-02
KR100446366B1 (ko) 2004-09-01

Similar Documents

Publication Publication Date Title
ID23503A (id) Garam-garam sertralina dan bentuk-bentuk sediaan lepas-lambat dari sertralina
WO1997025955A3 (en) Sanitary napkin with perfume-bearing microcapsule adhesive
EP0935963A3 (en) The use of MMP-13 selective inhibitors for the treatment of osteoarthritis and other matrix metalloproteinase-mediated disorders
CA2116238A1 (en) Oral 1 .alpha.-hydroxyprevitamin d
GT199800126A (es) Terapia de combinacion.
MX9204268A (es) Una composicion para la liberacion prolongada y controlada de substancias medicamentosas y un proceso para preparar la misma.
NO20000413D0 (no) Karbamyloksyforbindelser som inhiberer leukocytt adhesjon mediert av VLA-4
EP1055425A3 (en) Ultra-mild, clear, aqueous, foamable skin cleanser
YU53899A (sh) Primena inhibitora ciklooksigenaze-2 u prevenciji kardiovaskularnih poremećaja
SE9803680L (sv) Strålningshärdbara, cyanoakrylatinnehållande ko mpositioner
BR9806213A (pt) Forma de dosagem transdérmica.
BG102696A (en) Antipsoriasic nail varnish
ITCO970020A0 (it) Valvola di sicurezza e di morosita'
DE69619341D1 (de) Sicherheitsblatt, dessen Dicke beinahe konstant ist
NO996519D0 (no) Doseringsformer av sertralin med forsinket frigjoering
TR28156A (tr) Fren ve baglanti balatalari icin sürtünme balatasi karisimi.
NO20001548L (no) Endotelinantagonist og en renin-angiotensinsystem inhibitor som et kombinert preparat
HUP0302738A2 (hu) SARP-1 alkalmazása scleroderma kezelésére és megelőzésére
FR2761641B1 (fr) Dispositif d'actionnement pour l'actionnement, notamment l'actionnement pneumatique d'un embrayage a friction
EA200000112A1 (ru) Новая композиция
BR9802363A (pt) Dispositivo para comando de um estado de embreamento de uma embreagem
KR950023564A (ko) 배력장치의 시일부재 빠짐방지장치
NO963856D0 (no) Peptider som inhiberer frigjöringen av pepsin
Reisman et al. Life on the frontier: The Jews of Alaska
ID21253A (id) Bahan insektisida 1,4-diaril-2,3-difluoro-2-butena dan bahan-bahan akrisida